{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-Hodgkin+Lymphoma&page=18", "query": { "condition": "Stage IV Non-Hodgkin Lymphoma", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 553, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-Hodgkin+Lymphoma&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Non-Hodgkin+Lymphoma&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T04:52:46.727Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00245037", "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Precancerous Condition" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2005-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245037" }, { "nct_id": "NCT00053157", "title": "Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "5 Years to 60 Years" }, "enrollment_count": 10, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2022-10-05", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053157" }, { "nct_id": "NCT00788125", "title": "Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Extragonadal Germ Cell Tumor", "Kidney Cancer", "Liver Cancer", "Lymphoma", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 7, "start_date": "2008-09-03", "completion_date": "2022-07-30", "has_results": true, "last_update_posted_date": "2023-07-14", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00788125" }, { "nct_id": "NCT00293345", "title": "3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Primary Central Nervous System Hodgkin Lymphoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "triapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293345" }, { "nct_id": "NCT00104975", "title": "Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2005-02", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104975" }, { "nct_id": "NCT03113500", "title": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult T-Cell Leukemia/Lymphoma", "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Angioimmunoblastic T-Cell Lymphoma", "Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma", "Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Hepatosplenic T-Cell Lymphoma", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-05-25", "completion_date": "2027-04-25", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 4, "location_summary": "Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113500" }, { "nct_id": "NCT00899951", "title": "Studying Fentanyl in Patients With Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fentanyl citrate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2007-10", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2013-04-18", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899951" }, { "nct_id": "NCT00003356", "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 58, "start_date": "1997-11", "completion_date": "2002-05", "has_results": false, "last_update_posted_date": "2013-10-16", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003356" }, { "nct_id": "NCT00049465", "title": "Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 9, "location_summary": "Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00049465" }, { "nct_id": "NCT05025800", "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Composite Lymphoma", "Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Follicular Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma", "Richter Syndrome" ], "interventions": [ { "name": "CD47 Antagonist ALX148", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-10-13", "completion_date": "2028-03-21", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-14T04:52:46.727Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025800" } ] }